SUSTAINED-RELEASE DELIVERY COMPOSITION AND A METHOD FOR STABILIZING PROTEINS IN THE MANUFACTURING PROCESS Russian patent published in 2020 - IPC A61K47/18 A61K47/40 A61K47/56 A61K9/64 A61K38/02 A61P27/02 

Abstract RU 2720412 C2

FIELD: medicine; pharmaceuticals.

SUBSTANCE: group of inventions relates to preparations for continuous delivery of active substances. Disclosed is a composition for treating an eye pathology, comprising particles, wherein the particles contain an anticalin, a biodegradable polymer and one or more adjuvant and are capable of sustained continuous release of anticalin for at least two months; biodegradable polymer contains a poly(d,l-lactide-co-glycolide) copolymer with 75 mol % polylactic acid and 25 mol % polyglycolic acid and has an intrinsic viscosity in range of 0.50 dl/g to 0.70 dl/g; one or more adjuvants contains sulphobutylether-beta-cyclodextrin, trehalose, arginine or a combination thereof; wherein said excipients are present in amount of 5 to 15 % by weight based on the total weight of the composition, and the anticalin is present in amount of 5 to 50 % by weight. Also disclosed is use of said composition for treating eye pathologies and an aqueous preparation containing anticalin and one or more of said excipients.

EFFECT: group of inventions provides stabilization of highly concentrated solution of anticalin by using said excipients.

4 cl, 9 dwg, 4 tbl, 8 ex

Similar patents RU2720412C2

Title Year Author Number
BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR LONG-TERM RELEASE OF PROTEIN 2013
  • Vu Sindi V.
  • Robinson Majkl R.
  • Berk Dzhejms Ej.
  • Khyuz Patrik M.
RU2676102C2
POLYMERIC PROTEIN MICROPARTICLES 2012
  • Chen Khanter
  • Uolsh Skott
RU2642664C2
POLYMER PROTEIN MICROPARTICLES 2012
  • Chen Hunter
  • Walsh Scott
RU2768492C2
PROTEINS AND PROTEIN CONJUGATES WITH HIGH HYDROPHOBICITY 2015
  • Rozendal Meri S.
  • Mantripragada Sankaram B.
  • Gomes Eliana B.
RU2712644C2
MODULAR PARTICLES FOR IMMUNOTHERAPY 2014
  • Fakhmi, Tarek
  • Khorsburg, Brajan
RU2672055C2
VELDORETID, HAVING POOR SOLUBILITY IN PHYSIOLOGICAL CONDITIONS, FOR USE IN TREATING ACROMEGALY, ACROMEGALY WITH MALIGNANT GROWTH, EXPRESSING SST-R5 TUMORS, TYPE 2 DIABETES, HYPERGLYCEMIA AND TUMORS ASSOCIATED WITH HORMONES 2017
  • Afargan, Majkl
RU2736590C2
OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES 2016
  • Koenig Patrick
  • Lee Chingwei Vivian
  • Rajagopal Karthikan
  • Famili Amin
  • Fuh Germaine
RU2763916C2
SUNITINIB-BASED COMPOSITIONS AND METHODS FOR USING THEM FOR TREATING EYE DISEASES 2015
  • Fu Tsze
  • Khejns Dzhasti
  • Kajs Dzhoshua
  • Yu Yun
  • Yan Min
  • Klilend Dzheffri
  • Stark Uolter Dzh.
  • Syuj Tsinguo
  • Yan Tszin
RU2729731C2
IL-6 ANTAGONISTS AND USES THEREOF 2013
  • Shmidt Majkl M.
  • Erbe Devid V.
  • Barns Tomas M.
  • Ferfajn Erik Stiven
  • Tisdejl Elison
RU2670943C9
USE OF VEGF ANTAGONIST FOR TREATING RETINOPATHY OF PREMATURITY 2014
  • Buryan Gabriela
  • Aksenov Sergej
RU2676303C2

RU 2 720 412 C2

Authors

Tran Sajmon Kh.

Vu Sindi

Dates

2020-04-29Published

2014-03-13Filed